Fig. 4: Progression-free survival based on investigator assessment (subgroup analysis). | npj Breast Cancer

Fig. 4: Progression-free survival based on investigator assessment (subgroup analysis).

From: A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer

Fig. 4

a Progression-free survival in pre/perimenopausal patients. b Progression-free survival in postmenopausal patients. c Progression-free survival in patients treated with first-line endocrine therapy. d Progression-free survival in patients treated with second-line endocrine therapy. The tick marks indicate censored data. CI confidence interval; HR hazard ratio; NE not estimable; PFS progression-free survival.

Back to article page